IP Library Granted Patent US 11,207,402
Granted Patent B2
US 11,207,402 · App. 16/408,730 · Granted Dec 28, 2021

Constructs for enhancing immune responses

Inventors: Hildegund C. J. Ertl (Villanova, PA); Marcio O. Lasaro (Maple Shade, NJ); Luis C. S. Ferreira (Sao Paulo, BR)
Assignee: The Wistar Institute of Anatomy and Biology
A61K39/245A61K39/12C07K14/005C12N7/00A61K2039/53A61K2039/57C07K2319/00C07K2319/10C12N2710/10043C12N2710/16622C12N2710/16634Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,207,402
App. No.
16/408,730
Granted
Dec 28, 2021
Kind
B2
Abstract

Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.

Claims (17)

1. A method of inducing an immune response comprising providing to a subject in need thereof a vaccine comprising a nucleic acid molecule which encodes a fusion protein, wherein the fusion protein comprises:

a. a first polypeptide segment comprising at least amino acids 1-240 of a mature Herpes simplex virus (HSV) glycoprotein D, wherein the first polypeptide segment does not comprise a full length mature glycoprotein D;

b. a second polypeptide segment comprising at least one antigen, wherein the at least one antigen is not an HSV glycoprotein D antigen, wherein the N terminus of the second polypeptide segment is linked to the C terminus of the first polypeptide segment; and

c. a third polypeptide segment comprising a C terminal portion of the HSV glycoprotein D, wherein the N terminus of the third polypeptide segment is linked to the C terminus of the second polypeptide segment.

2. The method of claim 1 , wherein the HSV is selected from the group consisting of HSV-1 and HSV-2.

3. The method of claim 2 , wherein the first polypeptide segment comprises an amino acid sequence selected from the group consisting of:

a. amino acids 26-265 of SEQ ID NO:27;

b. amino acids 26-265 of SEQ ID NO:29;

c. amino acids 1-244 of the glycoprotein D;

d. amino acids 1-288 of the glycoprotein D; and

e. amino acids 1-294 of a mature HSV glycoprotein D with the exception that amino acid 294 is alanine instead of tryptophan.

4. The method of claim 3 , wherein the first polypeptide segment is encoded by a nucleic acid sequence comprising nucleotides 76-795 of SEQ ID NO:26; or nucleotides 350-1069 of SEQ ID NO:28.

5. The method of claim 1 , wherein the nucleic acid molecule is in a viral vector.

6. The method of claim 1 , wherein the nucleic acid molecule is naked DNA.

7. The method of claim 1 , wherein the nucleic acid molecule is in a bacterial vector.

8. The method of claim 1 , wherein the second polypeptide segment comprises the HPV E5 protein, the HPV E6 protein, and the HPV E7 protein.

9. The method of claim 1 , wherein the third polypeptide segment comprises the transmembrane domain of the HSV glycoprotein D.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 3, 2024
From: WISTAR INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066001/0811 →
Continuity (6)
Continuation 15639296 · Jun 30, 2017
Continuation 14628784 · Feb 23, 2015
Continuation 13239771 · Sep 22, 2011
Continuation 12438889
Provisional Application 60840526 · Aug 28, 2006
Related Publication 20190275143A1 · Sep 12, 2019
Cited By (2)
US 12,390,525 US 12,391,959